Ota Hiroaki, Fujimoto Daichi, Negi Yoshiki, Murata Takashi, Tokuda Mayuko, Higashiyama Tomoki, Tada Akio, Minami Toshiyuki, Otsuki Taiichiro, Mikami Koji, Takahashi Ryo, Kuribayashi Kozo, Kijima Takashi
Department of Respiratory Medicine and Hematology Hyogo Medical University Nishinomiya Hyogo Japan.
Respirol Case Rep. 2025 Apr 21;13(4):e70180. doi: 10.1002/rcr2.70180. eCollection 2025 Apr.
Steroid-refractory immune-related pneumonitis is a clinical challenge with limited evidence-based treatment strategies. Current guidelines recommend the use of immunosuppressants; however, the optimal type and dosage of these agents remain unclear. Herein, we report a case of steroid-refractory immune-related pneumonitis that was successfully treated with mycophenolate mofetil (MMF). The patient did not respond to high-dose steroid therapy as initial treatment but showed significant improvement in both subjective symptoms and imaging findings after the additional administration of MMF. Subsequent tapering of the MMF dose led to worsening imaging findings, which improved upon re-escalation of the MMF dose. This case highlights the potential efficacy of MMF for the treatment of steroid-refractory immune-related pneumonitis and provides valuable insights into the administration of MMF and its potential role in managing similar cases.
类固醇难治性免疫相关性肺炎是一个临床难题,基于证据的治疗策略有限。当前指南推荐使用免疫抑制剂;然而,这些药物的最佳类型和剂量仍不明确。在此,我们报告一例类固醇难治性免疫相关性肺炎患者,该患者成功接受霉酚酸酯(MMF)治疗。患者作为初始治疗对高剂量类固醇治疗无反应,但在加用MMF后主观症状和影像学表现均有显著改善。随后MMF剂量逐渐减少导致影像学表现恶化,而MMF剂量再次增加后病情改善。该病例突出了MMF治疗类固醇难治性免疫相关性肺炎的潜在疗效,并为MMF的给药及其在管理类似病例中的潜在作用提供了有价值的见解。